Can Dasatinib be used in children?

Dasatinib (Dasatinib) is a drug used to treat chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). Currently, the U.S. Food and Drug Administration (FDA) has approved dasatinib for the treatment of pediatric patients 1 year old and above. However, there are insufficient research data on the safety and effectiveness of dasatinib in children younger than 1 year of age. When children have certain types of leukemia, other treatments, such as chemotherapy and radiation, are often used. These treatments have been widely used in children and have long-term clinical experience.

Before considering dasatinib, doctors will weigh the risks and benefits of treatment. Dasatinib blocks the activity of an abnormal protein that signals cancer cells to multiply, which helps stop the spread and growth of cancer cells. Dasatinib, branded asSprycel, comes in tablet form. Dasatinib can be given orally to pediatric patients at approximately the same time each day, with or on an empty stomach, and should be taken exactly as recommended by the doctor, even if the patient is feeling better. The recommended dose of dasatinib is based on body weight. If a child vomits within 30 minutes of taking the drug, take another dose. If you vomit within 30 minutes of taking your second dose, do not take another dose.

In general, although dasatinib can be used to treat pediatric patients in certain circumstances, physician recommendations and precautions must be strictly followed during use. At the same time, further research and evaluation are needed to determine its safety and effectiveness for infants under 1 year old and pediatric patients with specific risk factors.